Prospects with docetaxel in the treatment of patients with breast cancer

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 7, 1997, Pages

  Marty, M ^a   Extra, J M ^a   Cottu, P H ^a   Espie M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast cancer; Combination regimen; Docetaxel; Phase I and II studies

Indexed keywords

ALTRETAMINE; ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; ELLIPTINIUM; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; HUMAN; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031441798     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(97)90007-1     Document Type: Conference Paper

References (8)

1. Chan S, Friedrichs K, Noël D, et al. A randomized phase III study of Taxotere® versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. Proc ASCO 1997, 16, 154a (540).
2. Peters WP, Jones RB, Vredenburgh J, et al. A large prospective randomized trial of high-dose alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc ASCO 1996, 15, 121(149).
3. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995, 13, 2483-2489.
4. Harris JR, Morrow M, Norton L, et al. Malignant tumours of the breast. In DeVita VT, Hellman S, Rosenberg SA eds: Cancer: Principles and Practice of Oncology (edn 5). Philadelphia, PA, Lippincott & Raven, 1996, Chapter 36, pp. 1557.
5. Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluoruracil versus fluoruracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996, 14, 35-45.
6. Wils J, Bliss JM, Coombes RC, et al. A multicentre randomized trial of tamoxifen vs tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer. Proc ASCO 1996, 109.
7. Culine S, Extra JM, Espié M, et al. Resultats prometteurs d'une chimiotherapie bimensuelle avec cyclophosphamide et epirubicine a forte dose dans le traitement d'induction du cancer du sein inflammatoire. Bull cancer (Paris) 1993, 80, 994-1000.
8. Bonneterre J, Roché H, Bremond A, et al. A randomized trial of adjuvant chemotherapy with FEC50 vs FEC100 for node-positive operable breast cancer early report. Proc ASCO 1996, 15, 104.